News

If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.

The market's perception of the pharmaceutical company has undeniably shifted.

The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut.

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of …

The odds of its new drug getting established in the U.K. are now much lower.

These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.